StockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

StockNews.com lowered shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

Several other research analysts have also recently commented on the stock. Royal Bank of Canada raised their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank raised their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Trading Down 0.2 %

Shares of AGIO opened at $33.22 on Friday. Agios Pharmaceuticals has a 12 month low of $24.88 and a 12 month high of $62.58. The firm’s 50 day moving average is $35.19 and its 200-day moving average is $43.36. The stock has a market capitalization of $1.89 billion, a PE ratio of 2.92 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.93% and a net margin of 2,051.38%. Equities research analysts predict that Agios Pharmaceuticals will post -0.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals in the third quarter worth $33,767,000. BNP Paribas Financial Markets grew its stake in shares of Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 1,570 shares during the last quarter. FMR LLC grew its stake in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the third quarter worth $892,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.